Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker

Prostate cancer is responsible for hundreds of thousands of annual deaths worldwide. The current gold standard in early detection of prostate cancer, the prostate specific antigen test, boasts a high sensitivity but low specificity, resulting in many unnecessary prostate biopsies. Thus, emphasis has...

Full description

Saved in:
Bibliographic Details
Published inOncotarget Vol. 9; no. 32; pp. 22359 - 22367
Main Authors Levin, Rachel A, Lund, Maria E, Truong, Quach, Wu, Angela, Shore, Neal D, Saltzstein, Daniel R, Concepcion, Raoul S, Paivanas, Thomas A, van Breda, Arletta, Beebe-Dimmer, Jennifer, Ruterbusch, Julie J, Wissmueller, Sandra, Campbell, Douglas H, Walsh, Bradley J
Format Journal Article
LanguageEnglish
Published United States Impact Journals LLC 27.04.2018
Subjects
Research Paper
3G5
prostate cancer
biomarker
glypican-1
MIL-38
Online AccessGet full text

Cover

More Information
Summary:Prostate cancer is responsible for hundreds of thousands of annual deaths worldwide. The current gold standard in early detection of prostate cancer, the prostate specific antigen test, boasts a high sensitivity but low specificity, resulting in many unnecessary prostate biopsies. Thus, emphasis has been placed on identifying new biomarkers to improve prostate cancer detection. Glypican-1 has recently been proposed as one such biomarker, however further exploration into its predictive power has been hindered by a lack of available, dependable glypican-1 immunoassays. Previously, we identified human glypican-1 as the antigenic target of the MIL-38 monoclonal antibody. Additionally, we have now generated another monoclonal antibody, 3G5, that also recognizes human glypican-1. Here we report the development of a reliable, custom Luminex assay that enables precise quantitation of circulating human glypican-1 in plasma and serum. Using this assay, we show for the first time that circulating glypican-1 levels can differentiate non-cancer (normal and benign prostatic hyperplasia) patients from prostate cancer patients, as well as benign prostatic hyperplasia patients alone from prostate cancer patients. Our findings strongly promote future investigation into the use of glypican-1 for early detection of prostate cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.25009